Clinical Trial

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

Name: A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors — clinical trial record (NCT06253130)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This study investigates the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EIK1003 in participants with advanced solid tumors.

Protocol Amendment History 1 change

notable Trial sites expanded: 53 -> 57 locations 2026-06-16

Trial Details

NCT Number	NCT06253130
Lead Sponsor	Eikon Therapeutics Collaborators: Impact Therapeutics, Inc.
Conditions	Advanced Solid Tumor
Enrollment	156 participants
Start Date	2023-12-11
Primary Completion	2027-06-01 (estimated)
Study Completion	2027-12-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-15